Skip to content

Category Archives: Emergent Bioslutions

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma

Wednesday, August 24, 2011

ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]

Also filed in Chief Medical Officer, Clinical trial, Fuad El-Hibri, Healthcare | Tagged , , , , | Comments (0)

Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference

Monday, August 15, 2011

ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, Investors | Tagged , , , , , | Comments (0)

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

Thursday, July 7, 2011

ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]

Also filed in Biothrax, Chief Executive Officer, Fuad El-Hibri, Healthcare, U.S. Food and Drug Administration | Tagged , , , , , | Comments (0)

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors

Monday, June 20, 2011

ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S. Chamber of Commerce is the world’s largest business federation representing the interests of more [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, entrepreneur | Tagged , , , , | Comments (0)

Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

Friday, June 10, 2011

ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, U.S. Food and Drug Administration | Tagged , , , , | Comments (0)

Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial

Monday, May 2, 2011

Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A
Study results expected to be available as early as mid-2012

ROCKVILLE, Md., Apr 28, 2011
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, South Africa | Tagged , , | Comments (0)

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Named Biotech CEO of the Year at the World Vaccine Congress

Friday, April 15, 2011

ROCKVILLE, Md., Apr 12, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been recognized as Biotech CEO of the Year during the Vaccine Industry Excellence (ViE) Awards at the World Vaccine Congress. The ViE awards showcase excellence and honor accomplishments of both individuals [...]

Also filed in Chief Executive Officer, El-Hibri, Food and Drug Administration, Fuad El-Hibri | Tagged , , , , | Comments (0)

Emergent BioSolutions Reports Financial Results for Full Year 2010

Wednesday, April 13, 2011

2010 revenues of $286.2 million
2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
2010 cash, investments and accounts receivable balance of $210.4 million
2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its [...]

Also filed in Board of directors, Business, Chief Executive Officer, Financial Results, Fuad El-Hibri | Tagged , , , , , | Comments (0)

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Tuesday, April 5, 2011

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, Healthcare Conference | Tagged , , , , | Comments (0)

Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine

Thursday, March 3, 2011

Comments expressed during tour of South African clinical trial site where Emergent’s TB vaccine candidate is expected to complete enrollment in April for its Phase IIb efficacy study
ROCKVILLE, Md., Feb 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that a joint delegation of Members of the European Parliament (MEPs) and [...]

Also filed in Chief Executive Officer, Clinical trial, Fuad El-Hibri, Research and development | Tagged , , , , , , | Comments (0)